Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865
Piper Sandler analyst Biren Amin maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $854 to $865.
Share
Why It Matters
An expert investor watcher raised their price goal for Regeneron a little bit. This hints they think the company is doing well and will keep growing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.